StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) stock

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.96−0.16 (-3.88%)

Close on Nov 17, 2026Market cap $317.61MP/E –Yield –

Atea Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Atea Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$152.07M. For fiscal 2025 it was -$132.03M. The highest annual figure on record is $296.73M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.03M–
FY2024Dec 31, 2024-$135.50M–
FY2023Dec 31, 2023-$85.40M–
FY2022Dec 31, 2022-$120.98M–
FY2021Dec 31, 2021-$87.01M-129.3%
FY2020Dec 31, 2020$296.73M–
FY2019Dec 31, 2019-$12.83M–
FY2018Dec 31, 2018-$7.91M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$37.08M–
Q1 FY2026Mar 31, 2026-$46.39M–
Q4 FY2025Dec 31, 2025-$28.22M–
Q3 FY2025Sep 30, 2025-$40.38M–
Q2 FY2025Jun 30, 2025-$32.87M–
Q1 FY2025Mar 31, 2025-$30.56M–
Q4 FY2024Dec 31, 2024-$30.40M–
Q3 FY2024Sep 30, 2024-$23.04M–
Q2 FY2024Jun 30, 2024-$42.20M–
Q1 FY2024Mar 31, 2024-$39.87M–
Q4 FY2023Dec 31, 2023-$21.83M–
Q3 FY2023Sep 30, 2023-$17.59M–
Q2 FY2023Jun 30, 2023-$16.12M–
Q1 FY2023Mar 31, 2023-$29.85M–
Q4 FY2022Dec 31, 2022-$21.55M–
Q3 FY2022Sep 30, 2022-$21.24M-194.0%
Q2 FY2022Jun 30, 2022-$19.19M–
Q1 FY2022Mar 31, 2022-$59.01M–
Q4 FY2021Dec 31, 2021-$75.42M-123.7%
Q3 FY2021Sep 30, 2021$22.60M–
Q2 FY2021Jun 30, 2021-$17.35M–
Q1 FY2021Mar 31, 2021-$16.84M–
Q4 FY2020Dec 31, 2020$318.52M–
Q3 FY2020Sep 30, 2020-$9.48M–
Q2 FY2020Jun 30, 2020-$7.80M–
Q1 FY2020Mar 31, 2020-$4.51M–
Q4 FY2019Dec 31, 2019-$3.94M–

More Atea Pharmaceuticals figures

See a number that looks wrong?